X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

To Grow Biologics Recipharm Buys Arranta And Vibalogics

Content Team by Content Team
22nd February 2022
in News
Recipharm supports FDA approval of Perrigos AB-rated generic product

Recipharm, the Swedish CDMO, which happens to be Moderna’s COVID-19 vaccine production partner, has undergone not one but two acquisitions in the week ending February 19th. This expansion is a part of a strategy that Recipharm has been eyeing since last summer. To bloat its biologics, Recipharm has opted for Arranta Bio and Vibalogics, with the former specialising in products that are microbiome therapeutics and are also into mRNA clinical production, whereas the latter focuses on oncolytic viruses, gene therapy, and viral vaccines too. Vibalogics will also help by providing process as well as analytical development, fill-finish services, testing, and manufacturing. There has been no mention of the commercials that Recipharm is paying for acquiring the two companies. There is also no communication on the details pertaining to the facilities and staff it wishes to acquire.

With the Arranta deal, which is expected to close by the end of March 2022, Recipharm will be able to access its strong microbiome platform, which has purification and fermentation expertise for naturally formed as well as developed bacteria consortia. What Arranta gives that platform is proprietary media, analytics, and crypreservative formulations that help in strengthening the viability of the biotherapeutic output.

In addition to the above, Arranta is also developing the plan to bring the drug development production and mRNA substance under a single roof, which will help it save time and also shield it from the ongoing supply chain challenges.

When we talk of Vibalogics, the CDMO, which is into virotherapy, comes with viral vectors and viruses for herpes, pox, and other virus classes concerning cancer and varied applications. Its customer base includes big pharma manufacturing companies and biotechs that are mid-sized or even startups. This double acquisition from Recipharm runs parallel to the almost buyout of Genlbet, a Portuguese CDMO that is into the manufacturing of clinical trial biological materials and also viral vectors. As is the case with the dual acquisition, the finances of Genlbet are also not in the public domain. Just prior to this deal, Recipharm also ended up signing an agreement with an unnamed drug maker that features in the top 10 list. As per the deal, it is expected that Recipharm may hire more than thirty employees over a period of four years.

Previous Post

Xanadu Executes Yale Tech In Developing Intranasal Booster

Next Post

MNC Pharmaceutical Giants Restructure Their India Presence

Related Posts

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Clinical Trials

Cancer Clinical Trials Get A Brand New Platform In Melbourne

3rd November 2022
Next Post
Drug Imagent For Therapeutic Platform

MNC Pharmaceutical Giants Restructure Their India Presence

Latest News

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In